| 1 day | -4.89% |
| Manager | Title | Age | Since |
|---|---|---|---|
Paul Lévesque
CEO | Chief Executive Officer | 62 | 2020-04-05 |
Philippe Dubuc
DFI | Director of Finance/CFO | 59 | 2016-02-23 |
| Chief Tech/Sci/R&D Officer | 63 | 2006-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Dawn Svoronos
CHM | Chairman | 72 | 2013-04-07 |
Andrew Molson
BRD | Director/Board Member | 58 | 2020-10-15 |
| Director/Board Member | 70 | 2017-05-15 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/3/25 | Marche | Executive/Senior Manager | 795 | 0.0017% | ||
| 9/29/25 | Marche | Executive/Senior Manager | 2,768 | 0.0060% | ||
| 9/29/25 | Marche | Executive/Senior Manager | 795 | 0.0017% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -4.89% | -2.40% | - | - | 148M | ||
| +1.14% | +6.61% | +40.79% | +145.27% | 1,286B | ||
| +0.79% | +3.45% | +45.84% | +92.04% | 688B | ||
| +0.20% | +1.28% | +26.97% | +114.41% | 521B | ||
| +0.80% | +1.67% | +41.99% | +72.18% | 386B | ||
| +0.55% | +0.70% | +59.02% | +45.79% | 364B | ||
| +1.01% | +1.47% | +28.02% | +62.71% | 302B | ||
| +0.34% | -0.31% | +3.16% | +37.93% | 287B | ||
| -0.30% | +1.14% | +38.29% | +70.56% | 252B | ||
| +0.08% | +0.71% | +34.44% | +123.99% | 208B | ||
| Average | +0.10% | +2.08% | +35.39% | +84.98% | 477B | |
| Weighted average by Cap. | +0.74% | +3.26% | +37.71% | +99.60% |
Employees
103
Sector
Pharmaceuticals
















